Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists.
Kerr KM, Bubendorf L, Lopez-Rios F, Khalil F, Roy-Chowdhuri S, Joubert P, Hartmann A, Guerini-Rocco E, Yatabe Y, Hofman P, Cooper WA, Dacic S (2024)
Publication Type: Journal article, Review article
Publication year: 2024
Journal
Book Volume: 84
Pages Range: 429-439
Journal Issue: 3
DOI: 10.1111/his.15078
Abstract
Many patients with non-small cell lung cancer do not receive guideline-recommended, biomarker-directed therapy, despite the potential for improved clinical outcomes. Access to timely, accurate, and comprehensive molecular profiling, including targetable protein overexpression, is essential to allow fully informed treatment decisions to be taken. In turn, this requires optimal tissue management to protect and maximize the use of this precious finite resource. Here, a group of leading thoracic pathologists recommend factors to consider for optimal tissue management. Starting from when lung cancer is first suspected, keeping predictive biomarker testing in the front of the mind should drive the development of practices and procedures that conserve tissue appropriately to support molecular characterization and treatment selection.
Authors with CRIS profile
Involved external institutions
University of Aberdeen
United Kingdom (GB)
Royal Prince Alfred Hospital
Australia (AU)
Universitätsspital Basel
Switzerland (CH)
Hospital Universitario 12 de Octubre
Spain (ES)
H. Lee Moffitt Cancer Center & Research Institute
United States (USA) (US)
University of Texas MD Anderson Cancer Center
United States (USA) (US)
CHU de Québec-Université Laval
Canada (CA)
European Institute of Oncology / Istituto Europeo di Oncologia (IEO)
Italy (IT)
Yale School of Medicine
United States (USA) (US)
National Cancer Center Hospital
Japan (JP)
Hôpital l'Archet (CHU de Nice)
France (FR)
United Kingdom (GB)
Royal Prince Alfred Hospital
Australia (AU)
Universitätsspital Basel
Switzerland (CH)
Hospital Universitario 12 de Octubre
Spain (ES)
H. Lee Moffitt Cancer Center & Research Institute
United States (USA) (US)
University of Texas MD Anderson Cancer Center
United States (USA) (US)
CHU de Québec-Université Laval
Canada (CA)
European Institute of Oncology / Istituto Europeo di Oncologia (IEO)
Italy (IT)
Yale School of Medicine
United States (USA) (US)
National Cancer Center Hospital
Japan (JP)
Hôpital l'Archet (CHU de Nice)
France (FR)
How to cite
APA:
Kerr, K.M., Bubendorf, L., Lopez-Rios, F., Khalil, F., Roy-Chowdhuri, S., Joubert, P.,... Dacic, S. (2024). Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists. Histopathology, 84(3), 429-439. https://dx.doi.org/10.1111/his.15078
MLA:
Kerr, Keith M., et al. "Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists." Histopathology 84.3 (2024): 429-439.
BibTeX: Download